Tom Powles
@tompowles1
Interested in Urology Cancers, biomarkers and drug development.
ID:1206580727296544769
16-12-2019 14:24:22
1,2K Tweets
10,6K Followers
58 Following
🚨 New Paper Alert! 🚨 Nivolumab plus Cabozantinib Maintains Long-Term Survival Benefit in Advanced Renal Cell Carcinoma
oncodaily.com/55697.html
ESMO Open Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD Maite Bourlon Mauricio Burotto Howard Gurney Elizabeth R Kessler @myesmo Yoshihiko Tomita…
Looking for teams for #uromigoslive24 to take on the team from LA. Hard it beat Tanya, Monty and Petros…..
Just out on ESMO Open
By our OncoAlert 🚨GU faculty Tom Powles Andrea Apolo, M.D. Toni Choueiri, MD and Team
Extended Follow Up from CheckMate 9ER
Report provides updated efficacy and safety data on Nivolumab plus Cabozantinib (NIVO + CABO) 🆚 sunitinib (SUN) for 1⃣st line treatment…
Just out in ESMO open ESMO - Eur. Oncology With 44.0 months of median follow-up nivolumab/cabozantinib continues to outperform sunitinib in M1 clear cell RCC. The 3 VEGF/TKI combinations have more similarities than differences and track each other with longer follow up gbr01.safelinks.protection.outlook.com/?url=https%3A%…